Drug Price Trends for NDC 42291-0511

Average Pharmacy Cost for 42291-0511

Drug Name	NDC	Price/Unit ($)	Unit	Date
No data available in table

Best Wholesale Price for NDC 42291-0511

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
PRIMIDONE 250MG TAB	AvKare, LLC	42291-0511-50	500	148.15	0.29630	2023-06-15 - 2028-06-14	FSS
PRIMIDONE 250MG TAB	AvKare, LLC	42291-0511-01	100	29.85	0.29850	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 42291-0511: Navigating the Pharmaceutical Landscape

The pharmaceutical industry is a complex and ever-evolving sector, with drug pricing and market dynamics playing crucial roles in shaping its future. In this comprehensive analysis, we'll delve into the market trends and price projections for the drug identified by the National Drug Code (NDC) 42291-0511. By examining various factors influencing the industry, we'll provide valuable insights for stakeholders navigating this challenging landscape.

Understanding the National Drug Code (NDC)

Before we dive into the specifics of NDC 42291-0511, it's essential to understand what the National Drug Code represents. The NDC is a unique, three-segment number assigned by the U.S. Food and Drug Administration (FDA) to human drugs in the United States[9]. It serves as a universal product identifier for human drugs and plays a crucial role in various aspects of the pharmaceutical supply chain.

Breaking Down NDC 42291-0511

The NDC 42291-0511 can be broken down into three segments:

1. Labeler Code (42291): Identifies the manufacturer, repackager, or distributor of the drug.
2. Product Code (05): Identifies the specific strength, dosage form, and formulation of the drug.
3. Package Code (11): Identifies the package size and type.

By understanding these components, we can gain insights into the drug's manufacturer and specific formulation, which are crucial factors in market analysis and price projections.

Current Market Trends in the Pharmaceutical Industry

The pharmaceutical industry is experiencing significant changes driven by various factors, including technological advancements, regulatory shifts, and evolving patient needs. Let's explore some of the key trends shaping the market in 2025 and beyond.

Digital Transformation and AI Integration

One of the most prominent trends in the pharmaceutical industry is the rapid adoption of digital technologies and artificial intelligence (AI). According to a recent survey:

More than 85% of biopharma executives say they are investing in data, AI and digital tools in 2025 to build supply chain resiliency[7].

This digital transformation is impacting various aspects of the industry, from drug discovery to clinical trials and supply chain management. AI-powered tools are helping companies accelerate research and development processes, optimize clinical trial recruitment, and enhance manufacturing efficiency.

Focus on Novel Modalities and Mechanisms of Action

Pharmaceutical companies are increasingly shifting their focus towards innovative treatment modalities and mechanisms of action (MOAs). This trend is driven by the need to address unmet medical needs and develop more effective therapies. Some emerging modalities include:

• Fusion proteins
• Oligonucleotide therapies
• Multispecific antibodies
• Antibody-drug conjugates
• Radioligand therapies
• Oncolytic viruses

These novel approaches are reshaping drug development pipelines and have the potential to revolutionize patient care across various therapeutic areas.

Emphasis on High Unmet Needs

Another significant trend is the industry's increased focus on therapeutic areas with high unmet needs. Many pharmaceutical companies are expanding beyond traditional core areas like oncology and immunology to address conditions with limited treatment options. For instance:

• Next-generation Alzheimer's drug candidates
• Advanced weight management therapies
• Cardiovascular treatments targeting Lp(a)
• mRNA-based cancer vaccines

This shift in focus not only addresses critical patient needs but also presents new market opportunities for pharmaceutical companies.

Factors Influencing Drug Pricing

Understanding the factors that influence drug pricing is crucial for accurate market analysis and price projections. Several key elements play a role in determining the price of pharmaceuticals, including NDC 42291-0511.

Research and Development Costs

The high costs associated with drug research and development significantly impact pricing strategies. According to industry estimates, bringing a new drug to market can cost upwards of $2.6 billion. These substantial investments need to be recouped through drug sales, influencing pricing decisions.

Regulatory Environment

The regulatory landscape plays a crucial role in shaping drug prices. Recent initiatives, such as the Medicare Drug Price Negotiation Program, are set to impact pricing strategies significantly. For instance:

Beginning in January 2026, Medicare Part D will implement negotiated prices for certain drugs, resulting in discounts ranging from 38% to 79% compared to list prices[2].

Such regulatory changes can have far-reaching effects on drug pricing across the industry.

Market Competition

The level of competition in the market for a particular drug or therapeutic area can significantly influence pricing. Factors such as the presence of generic alternatives, biosimilars, or competing branded drugs can put pressure on prices. For example, the entry of biosimilars in certain therapeutic areas has led to price reductions for originator biologics.

Manufacturing and Supply Chain Costs

The costs associated with drug manufacturing and supply chain management also play a role in pricing decisions. As companies invest in advanced manufacturing technologies and supply chain optimization, these costs can impact the final price of drugs.

Price Projections for NDC 42291-0511

While specific price projections for NDC 42291-0511 would require detailed proprietary information, we can make some general observations based on industry trends and available data.

Historical Price Trends

Analyzing historical price trends can provide insights into potential future pricing. For instance, a study of selected drugs showed:

Nine out of ten drugs selected for Medicare price negotiations had list price increases ranging from 20% to 55% between 2018 and 2023[2].

This trend suggests that many drugs have experienced significant price increases in recent years. However, it's important to note that past performance doesn't guarantee future results, especially given the changing regulatory landscape.

Impact of Medicare Drug Price Negotiation Program

The implementation of the Medicare Drug Price Negotiation Program is expected to have a significant impact on drug pricing, particularly for drugs covered under Medicare Part D. If NDC 42291-0511 falls under this program, it could potentially see price reductions in line with the projected discounts of 38% to 79% compared to list prices[2].

Market Dynamics and Competition

The competitive landscape for NDC 42291-0511 will play a crucial role in its price projections. Factors to consider include:

• The presence of generic alternatives or biosimilars
• The drug's position in its therapeutic class
• The potential entry of new competitors in the market

These elements can exert upward or downward pressure on prices, depending on the specific market dynamics.

Strategies for Pharmaceutical Companies in 2025

Given the complex and evolving nature of the pharmaceutical market, companies need to adopt strategic approaches to navigate the challenges and opportunities ahead. Here are some key strategies that pharmaceutical companies, including those involved with NDC 42291-0511, should consider:

Embracing Digital Transformation

As highlighted earlier, digital transformation is a crucial trend in the industry. Companies should invest in:

• AI-powered drug discovery platforms
• Advanced data analytics for clinical trial optimization
• Digital tools for supply chain management and manufacturing efficiency

By leveraging these technologies, companies can potentially reduce costs, accelerate time-to-market, and improve overall operational efficiency.

Focusing on Value-Based Pricing

With increasing scrutiny on drug prices, pharmaceutical companies should consider adopting value-based pricing models. This approach involves setting prices based on the demonstrated value of the drug in terms of patient outcomes and overall healthcare cost savings. For NDC 42291-0511, this could involve:

• Conducting robust health economic studies
• Engaging with payers and healthcare providers to demonstrate value
• Developing innovative pricing models that align with patient outcomes

Diversifying Product Portfolios

To mitigate risks associated with patent expirations and market competition, pharmaceutical companies should focus on diversifying their product portfolios. This could involve:

• Investing in novel modalities and mechanisms of action
• Expanding into therapeutic areas with high unmet needs
• Pursuing strategic partnerships or acquisitions to access new technologies or markets

Optimizing Supply Chains

Given the increasing focus on supply chain resilience, companies should invest in optimizing their manufacturing and distribution networks. This could involve:

• Implementing smart manufacturing technologies
• Diversifying supplier networks to reduce risks
• Investing in local manufacturing capabilities to address geopolitical concerns

Future Outlook for the Pharmaceutical Industry

As we look towards the future of the pharmaceutical industry, several key trends and developments are likely to shape the landscape:

Continued Innovation in Drug Development

The pace of innovation in drug development is expected to accelerate, driven by advancements in areas such as:

• Precision medicine and personalized therapies
• Gene editing technologies like CRISPR
• AI-powered drug discovery platforms

These innovations have the potential to revolutionize treatment paradigms across various therapeutic areas.

Evolving Regulatory Landscape

The regulatory environment for pharmaceuticals is likely to continue evolving, with a focus on:

• Accelerating approval processes for innovative therapies
• Implementing new pricing controls and transparency measures
• Addressing global harmonization of regulatory standards

Companies will need to stay agile and adapt to these changing regulatory requirements.

Shift Towards Patient-Centric Models

The industry is expected to continue its shift towards more patient-centric models, emphasizing:

• Real-world evidence and patient-reported outcomes
• Digital health solutions and remote patient monitoring
• Personalized treatment approaches based on genetic and biomarker data

This focus on patient-centricity is likely to influence both drug development strategies and pricing models.

Key Takeaways

• The pharmaceutical industry is undergoing significant transformation, driven by digital technologies, novel treatment modalities, and changing regulatory landscapes.
• Drug pricing, including for NDC 42291-0511, is influenced by factors such as R&D costs, regulatory environment, market competition, and manufacturing expenses.
• The implementation of programs like the Medicare Drug Price Negotiation Program is expected to have a substantial impact on drug pricing strategies.
• Companies need to embrace digital transformation, focus on value-based pricing, diversify product portfolios, and optimize supply chains to succeed in the evolving market.
• The future of the pharmaceutical industry will be shaped by continued innovation in drug development, evolving regulations, and a shift towards patient-centric models.

FAQs

1. Q: How does the National Drug Code (NDC) system work? A: The NDC is a unique, three-segment number assigned by the FDA to identify human drugs in the United States. It consists of a labeler code (identifying the manufacturer), a product code (specifying the drug's strength and formulation), and a package code (indicating package size and type).

2. Q: What impact will the Medicare Drug Price Negotiation Program have on drug pricing? A: The program is expected to result in significant discounts for selected drugs, ranging from 38% to 79% compared to list prices. This could lead to broader changes in pricing strategies across the pharmaceutical industry.

3. Q: How are AI and digital technologies transforming the pharmaceutical industry? A: AI and digital technologies are being used to accelerate drug discovery, optimize clinical trials, enhance manufacturing efficiency, and improve supply chain management. These advancements are expected to reduce costs and accelerate time-to-market for new drugs.

4. Q: What are some emerging trends in drug development? A: Key trends include a focus on novel modalities (such as gene therapies and mRNA-based treatments), targeting diseases with high unmet needs, and leveraging precision medicine approaches for more personalized treatments.

5. Q: How can pharmaceutical companies adapt to the changing market landscape? A: Companies can adapt by embracing digital transformation, focusing on value-based pricing models, diversifying their product portfolios, optimizing supply chains, and adopting patient-centric approaches to drug development and commercialization.

Sources cited: [2] https://aspe.hhs.gov/sites/default/files/documents/3e8abec86039ac0ed674a8c5fac492e3/price-change-over-time-brief.pdf [7] https://www.zs.com/insights/pharmaceutical-trends-2025-outlook-ai-supplychain-and-beyond [9] https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory